Nicotinamide Supplements: What Niacinamide Does (and Doesn't Do) for NAD+

Written by the Nuvirox Research Team

Short answer: nicotinamide has real, proven benefits in specific contexts — especially skin health and sun damage protection — but it is not the strongest NAD+ booster in the supplement landscape. The confusion starts with naming. "Nicotinamide," "niacinamide," and "vitamin B3" are all terms for the same compound (the amide form of nicotinic acid). It is related to, but chemically distinct from, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Depending on what you are trying to accomplish, nicotinamide may be exactly the right supplement — or it may be the wrong tool. This article separates those use cases clearly.

What is nicotinamide and how does it relate to NAD+?

Nicotinamide (NAM) is a water-soluble form of vitamin B3 and the most common dietary precursor to NAD+. Foods including meat, fish, whole grains, and legumes provide nicotinamide, which cells convert to NAD+ through the salvage pathway. This conversion requires an enzyme called NAMPT (nicotinamide phosphoribosyltransferase), which is the rate-limiting step — and this is where nicotinamide's limitation as a supplement emerges.

NMN and NR bypass the NAMPT step entirely: NMN converts to NAD+ via NMNAT, and NR is first converted to NMN by NRK, also bypassing NAMPT. Because NAMPT activity is not unlimited and declines with age, flooding the pathway with nicotinamide may not efficiently drive NAD+ synthesis in the way that NAMPT-bypassing precursors can. A 2026 randomized head-to-head trial in Nature Metabolism confirmed this directly: 14 days of NR or NMN supplementation significantly raised circulatory NAD+ in healthy participants, while nicotinamide at comparable doses did not produce significant increases. A separate analysis found that 500 mg nicotinamide elevated blood NAD+ in healthy men while 100 mg did not — suggesting dose matters considerably, but even high-dose NAM is a weaker NAD+ elevator than NAMPT-bypassing precursors. For a deeper comparison of NR and NMN specifically, see our article on NR vs. NMN vs. NAD+.

Illustrative summary of relative NAD+ elevation in published human trials. Bar heights represent approximate ranges across studies and are not drawn from a single head-to-head trial. Actual results vary by dose, population, and measurement method.

What human studies on nicotinamide supplements actually show

The strongest evidence for any NAD+ pathway supplement in humans is for nicotinamide — in a very specific context. The ONTRAC trial (Chen AC et al., New England Journal of Medicine, 2015; PMID: 26488693) was a Phase 3 randomized, double-blind, placebo-controlled trial in 386 high-risk immunocompetent patients (at least two prior non-melanoma skin cancers). Participants received oral nicotinamide 500 mg twice daily (1,000 mg/day total) or placebo for 12 months. The nicotinamide group had a 23% lower rate of new non-melanoma skin cancers (p = 0.02), a 30% lower rate of new squamous cell carcinomas (p = 0.05), and significantly lower actinic keratosis counts throughout the treatment period (11–20% lower at various time points, all p ≤ 0.05). No significant adverse event differences were found between groups. Importantly, the protective effect did not persist after nicotinamide was discontinued — suggesting it requires ongoing supplementation to maintain benefit.

The null finding in a more vulnerable population: A subsequent Phase 3 trial (Allen et al., New England Journal of Medicine, 2023) tested the same dose (500 mg twice daily for 12 months) in organ-transplant recipients — a population with immune suppression that substantially increases skin cancer risk. In this trial, oral nicotinamide did not significantly reduce keratinocyte cancers or actinic keratoses compared to placebo. This is an important counterpoint: the skin cancer protection observed in ONTRAC may be specific to immunocompetent high-risk individuals and does not appear to extend to immunosuppressed transplant recipients. The differential response is not fully understood and underscores that population matters enormously in extrapolating supplement evidence. (Allen NC et al., N Engl J Med. 2023;388(9):804–812. PMID: 36856616.)

Skin aging and cosmeceutical evidence: A substantial body of clinical trial work — primarily using topical nicotinamide at 5% concentrations — demonstrates improvements in fine lines, hyperpigmentation, skin barrier function, and uneven tone compared to placebo. A 2021 review in Antioxidants (PMID: PMC8389214) summarized evidence showing that topical nicotinamide restores the cellular NAD+ pool, attenuates oxidative stress, and enhances the skin's extracellular matrix. The dermatology evidence for topical nicotinamide is among the most robust in cosmeceutical science. Oral nicotinamide's role in systemic skin-related outcomes is specifically supported by the ONTRAC trial; its role in cosmetic aging (wrinkles, elasticity) through oral supplementation is less clearly established.

Nicotinamide vs. niacin: why they are not the same

A frequent source of confusion: niacin (nicotinic acid) and nicotinamide (niacinamide) are both forms of vitamin B3, but they behave very differently as supplements. Niacin at therapeutic doses (1–3 g/day) is an effective HDL-raising and triglyceride-lowering agent used in cardiovascular medicine — but it causes a well-known "flush" (vasodilatory skin reaction) that many users find intolerable. Nicotinamide does not cause flushing. It also does not have niacin's lipid-lowering effects. A meta-analysis (Zhong O et al., Nutrition & Metabolism, 2022; PMC8932245) found that among NAD+ precursors, niacin had the most significant effect on lipid metabolism, while nicotinamide (NAM) supplementation did not significantly improve lipid markers. When you see "B3" on a supplement label, confirming which form is present is essential.

What users report

People supplementing with oral nicotinamide (typically 500 mg once or twice daily) tend to report fewer subjective effects than those taking NMN or NR — which aligns with the clinical data showing weaker NAD+ elevation. Users in online health communities often describe nicotinamide as "background maintenance" rather than a supplement with a noticeable effect. The exception is within dermatology-adjacent communities, where oral nicotinamide is discussed in the context of actinic keratoses and skin cancer risk in high-sun-exposure individuals, referencing the ONTRAC trial specifically. Some users report mild nausea at 500 mg twice daily, which tends to resolve with food. These are anecdotal reports and do not establish causation.

Nicotinamide supplementation: dosing and timing

The dose with the strongest human evidence for skin cancer chemoprevention is 500 mg twice daily (1,000 mg total), consistent with the ONTRAC trial protocol. For NAD+ elevation specifically, 500 mg daily has shown some effect in healthy men in at least one study, though the magnitude is smaller than what NMN or NR produce at their typical doses. There is no established dose for general "healthy aging" supplementation with nicotinamide because no trial has tested this indication directly in a well-powered RCT. If you are taking nicotinamide for skin-health reasons, the ONTRAC protocol (500 mg twice daily) is the best-supported benchmark. Dosing above 3,000 mg/day has been associated with liver enzyme elevations in some reports and should be avoided without medical supervision.

Nicotinamide does not require timing relative to meals for efficacy, but taking it with food may reduce gastrointestinal discomfort. It is water-soluble, so there is no fat requirement for absorption (unlike fat-soluble vitamins).

What nicotinamide won't do

Nicotinamide is not the most potent NAD+ booster available — if raising blood or cellular NAD+ levels is your primary goal, NMN and NR have stronger evidence for that specific outcome. Nicotinamide will not produce the cholesterol-lowering effects of niacin. Its skin cancer prevention benefit appears specific to immunocompetent individuals with a documented history of non-melanoma skin cancer, not a general population benefit without that risk profile. It is not a substitute for sunscreen or dermatological monitoring in people at elevated skin cancer risk. And as with all NAD+ pathway supplements, it has not been shown in any human trial to extend lifespan, reverse aging, or prevent any specific disease in the general population — claims that exceed what the evidence currently supports. If you have a personal or family history of skin cancer, the ONTRAC evidence is worth discussing with a dermatologist specifically. For a broader look at NAD+ supplement benefits across the evidence base, see NAD+ Benefits: What the Human Evidence Actually Supports.

Frequently asked questions

Is nicotinamide the same as niacinamide?
Yes, exactly. Nicotinamide and niacinamide are different names for the same compound — the amide form of vitamin B3. You will see both terms on supplement labels, in research papers, and in skincare products. They are interchangeable.

Is nicotinamide the same as NMN?
No. NMN (nicotinamide mononucleotide) contains nicotinamide as part of its molecular structure but is a distinct compound with a phosphate group attached. NMN bypasses the NAMPT rate-limiting step in the NAD+ salvage pathway; nicotinamide does not. They are different supplements with different mechanisms and different evidence bases.

Should I take nicotinamide instead of NMN?
It depends on your goal. If you want to raise NAD+ levels in blood tests, NMN and NR have stronger evidence. If you have a history of non-melanoma skin cancers and are immunocompetent, the ONTRAC data for oral nicotinamide is compelling and should be discussed with your dermatologist. Nicotinamide is significantly less expensive than NMN, which matters for long-term supplementation feasibility.

Can you take nicotinamide and NMN together?
There is no clinical evidence from human trials directly testing this combination. Theoretically, adding extra nicotinamide to the system when your cells are already converting NMN to NAD+ adds little incremental benefit for NAD+ elevation. However, nicotinamide at 500 mg twice daily for skin cancer prevention is a standalone indication with its own evidence base, separate from NAD+ optimization goals. Discuss any combination protocol with a healthcare provider.

Does nicotinamide cause liver damage?
At typical supplement doses (up to 1,000 mg/day), liver toxicity has not been a significant concern in clinical trials. Reports of elevated liver enzymes have appeared at higher doses (generally above 3,000 mg/day) and in specific populations. The ONTRAC trial at 1,000 mg/day found no significant adverse event differences from placebo. If you are taking high-dose nicotinamide, periodic liver enzyme monitoring is a reasonable precaution, particularly if you are already on other medications.

The bottom line

Nicotinamide is not a second-tier NAD+ supplement — it is a different tool with a different job. Its strongest human evidence is in skin cancer chemoprevention in high-risk populations, where a Phase 3 NEJM trial showed a 23% reduction in new non-melanoma skin cancers. That is clinically meaningful and often overlooked in discussions that frame nicotinamide simply as a weaker version of NMN. Where it falls short is in raising blood NAD+ levels compared to NAMPT-bypassing precursors like NMN and NR; for that goal, the biochemistry and the human trial data favor those newer compounds. Nicotinamide's low cost, absence of flushing, and strong safety record make it worth understanding clearly. Know what it does well, know where its limits are, and choose based on your actual goal rather than marketing that blurs these distinctions.

---

References

1. Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618–1626. doi: 10.1056/NEJMoa1506197. PMID: 26488693.
2. Allen NC, Martin AJ, Snaidr VA, et al. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. N Engl J Med. 2023;388(9):804–812. doi: 10.1056/NEJMoa2203086. PMID: 36856616.
3. Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1:47–57. [Background on NAD+ pathway biochemistry.]
4. Zhong O, Wang J, Tan Y, Lei X, Tang Z. Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis. Nutr Metab (Lond). 2022;19:20. doi: 10.1186/s12986-022-00653-9. PMCID: PMC8932245.
5. Boo YC. Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation. Antioxidants. 2021;10(8):1315. doi: 10.3390/antiox10081315. PMCID: PMC8389214.
6. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. J Gerontol A Biol Sci Med Sci. 2023;78(12):2435–2448. doi: 10.1093/gerona/glad106. PMID: 37068054; PMCID: PMC10692436.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.